Viewing Study NCT00721591


Ignite Creation Date: 2025-12-18 @ 4:27 AM
Ignite Modification Date: 2025-12-23 @ 9:59 PM
Study NCT ID: NCT00721591
Status: None
Last Update Posted: 2016-11-01 00:00:00
First Post: 2008-07-22 00:00:00
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy
Sponsor: None
Organization:

Study Overview

Official Title: Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy
Status: None
Status Verified Date: 2016-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study's specific objectives include:

1. Evaluating pharmacokinetic (concentration-time) and pharmacodynamic (concentration- effect) parameters for dalteparin and UFH prior to pregnancy, during the 1st, 2nd and 3rd trimesters and postpartum, using revised dosing protocols based on previous study.
2. Determining therapeutic response to the heparins, i.e. live birth rate and lack of maternal or fetal complications, in relation to drug exposure, based on AUC.
3. Documenting maternal and fetal complications during pregnancy for dalteparin and UFH, using the revised dosing protocols.
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: